Moderna/Merck begins late-stage study of skin cancer vaccine combination

Data from a mid-stage study had shown that the combination cut the risk of recurrence or death of melanoma, the most deadly form of skin cancer, by 44per cent when compared with Keytruda alone.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/xoeQE9h
via